Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
COLISTIN MESILATE SODIUM
Zambon S.p.A.
J01XB01
COLISTIN MESILATE SODIUM
1 million International Unit
Powder for nebuliser solution
Product subject to prescription which may not be renewed (A)
Polymixins
Authorised
2018-01-19
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Promixin, 1 million International Units (IU), Powder for Nebuliser Solution. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 1 million International Units (IU) which is approximately equivalent to 80 mg of Colistimethate Sodium. 3 PHARMACEUTICAL FORM Powder for nebuliser solution. The powder is white to off-white. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Promixin is indicated for the management in adult and paediatric of chronic pulmonary infections due to_ Pseudomonas_ _aeruginosa_ in patients with cystic fibrosis (see section 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION It is recommended that colistimethate sodium (CMS) should be administered under the supervision of physicians with appropriate experience in its use. Posology The dosage can be adjusted depending on the severity of the condition and clinical response. Recommended dose range: _Administration via inhalation_ _Adults, adolescents and children_ _2 years_ 1-2 MIU two to three times per day (max 6 MIU/day) _Children < 2 years_ 0.5-1 MIU twice daily (max 2 MIU/ day) Relevant clinical guidance on treatment regimens, including duration of treatment, periodicity and co-administration of other antibacterial agents should be adhered to. _Older people_ Dose adjustment is not considered necessary. _Renal impairment_ Dose adjustment is not considered necessary, however caution is advised in patients with renal impairment (see sections 4.4 and 5.2). _Hepatic impairment_ Dose adjustment is not considered necessary. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ __ Read the complete document